Chugai To Deploy Chiome’s MAb Generation Technology
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Chugai Pharmaceutical signed a research agreement with a local Tokyo-based bio venture, Chiome Bioscience to deploy Chiome's Autonomously Diversifying Library system, a monoclonal antibody generation technology for developing monoclonal antibodies against various target proteins owned by Chugai, a Chugai spokesman confirmed Jan. 9